公开(公告)号：US20240190963A1

公开(公告)日：2024-06-13

申请号：US18468097

申请日：2023-09-15

Applicant: Bristol-Myers Squibb Company

Inventor： Prabhu Seshaiyer Bhagavatheeswaran ,  Nicholas Allan John Botwood ,  Han Chang ,  Yali Fu ,  William J. Geese ,  George A. Green, IV ,  Diane Healey ,  Sabine Maier ,  Faith E. Nathan ,  Abderrahim Oukessou ,  Giovanni Selvaggi ,  Joseph Daniel Szustakowski

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2818 ,  A61P35/00 ,  C07K16/2827 ,  C07K16/30 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/76

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

公开(公告)号：US20210032344A1

公开(公告)日：2021-02-04

申请号：US17044163

申请日：2019-03-29

Applicant: Bristol-Myers Squibb Company

Inventor： Prabhu Seshaiyer Bhagavatheeswaran ,  Nicholas Allan John Botwood ,  Han Chang ,  Yali Fu ,  William J. Geese ,  George A. Green, IV ,  Diane Healey ,  Sabine Maier ,  Faith E. Nathan ,  Abderrahim Oukessou ,  Giovanni Selvaggi ,  Joseph Daniel Szustakowski

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.